[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Mitsuno
Yuzo
Y
Department of Gastroenterology, Faculty of Medicine, University of Tokyo.
Yoshida
Haruhiko
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017291:Clarithromycin; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D007769:Lactams; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome; D047090:beta-Lactams
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D007769:Lactams; D054328:Proton Pump Inhibitors; D047090:beta-Lactams; D064747:Lansoprazole; D000658:Amoxicillin; C107057:fropenem; D017291:Clarithromycin; D009853:Omeprazole